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Abstract
Introduction: Antiretroviral changes (single drug substitutions and regimen switches) limit treatment options and introduce
challenges such as increased cost, monitoring and adherence difficulties. Patterns of drug substitutions and regimen
switches from stavudine (d4T) and zidovudine (AZT) regimens have been well described but data on tenofovir (TDF) are
more limited. This study describes the patterns and risk factors for drug changes of these antiretroviral drugs in adults.
Method: This retrospective cohort study included HIV positive, antiretroviral treatment (ART) naı¨ve adults aged $18 years
who started ART with two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase
inhibitor. Follow-up was censored at first drug change and analysis focused on NRTI changes only.
Results: Between September 2002 and April 2011, 5095 adults initiated ART in Gugulethu. This comprised 948 subjects on
TDF, 3438 on d4T and 709 subjects on AZT. Virological suppression rates at 1 year, regimen switching due to virological
failure and overall losses to the programme were similar across the three groups. TDF had the lowest incidence rate of drug
substitutions (2.6 per 100 P/Ys) compared to 17.9 for d4T and 8.5 per 100 P/Ys for AZT. Adverse drug reactions (ADRs)
accounted for the majority of drug substitutions of d4T. Multivariate analysis showed that increasing age, female sex and
d4T exposure were associated with increased hazard of drug substitution due to ADRs. Conversely, TDF exposure was
associated with a substantially lower risk of substitution (adjusted hazards ratio 0.38; 95% CI 0.20–0.72).
Conclusion: Regimen switches and virological suppression were similar for patients exposed to TDF, d4T and AZT,
suggesting all regimens were equally effective. However, TDF was better tolerated with a substantially lower rate of drug
substitutions due to ADRs.
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Introduction
Antiretroviral therapy (ART) toxicity leads to drug changes
which are especially problematic in resource limited settings where
treatment options are limited. Prior to 2009, stavudine (d4T) was
widely used as part of first-line ART in South Africa [1]. Despite
d4T having good virological efficacy, it has poor tolerability and is
frequently associated with peripheral neuropathy and lipodystro-
phy that may affect up to 21% and 46% of patients respectively
[2]. In light of compelling safety data against d4T, the World
Health Organization (WHO) in the 2010 ART guidelines
recommended replacement of d4T with tenofovir (TDF), a
nucleotide reverse transcriptase inhibitor in first-line ART
regimens with a better safety profile [3,4].
In South Africa, use of TDF was phased in around April,
2010 [5]. A disadvantage of TDF, is that it is significantly more
expensive than d4T, with an estimated yearly cost for a TDF
regimen being $675 compared to $121 for a d4T regimen [6].
However, cost effectiveness analyses using South Africa data
suggests that TDF based regimens have almost 12 months more
quality adjusted life expectancy compared to d4T regimens [6].
Thus to provide a clear justification for use of this regimen,
comparative data are needed on the virological efficacy and
rates of toxicity associated with these regimens.
Whereas data on drug substitutions for adverse drug reactions
(ADRs) and regimen changes due to treatment failure have been
well described for d4T and zidovudine (AZT)[7–11], data on TDF
are limited, particularly in sub-Saharan Africa where the drug has
been in use for a much shorter duration [10,12]. TDF has been
used widely in developed countries since 2002 [13] so most data
relating to TDF toxicity are derived from these countries. Drug
substitution due to renal impairment ranges from 0% to
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approximately 2% in studies conducted in developed settings [14–
16].
In South Africa, TDF is indicated for all new patients starting
ART and in those who develop ADRs to d4T or AZT whereas
existing patients already receiving d4T or AZT-containing
regimens and who have not experienced ADRs are retained on
these drugs.
The objectives of this study were to describe incidence rates of
drug substitutions and regimen switches due to virological failure
among patients receiving regimens containing d4T, AZT or TDF
in a large peri-urban area in Gugulethu, Cape Town, South
Africa. In addition, to characterize the reasons and risk factors for
ADR-related drug substitutions.
Methods
Ethics Statement
Data collected for this study received ethical approval from the
University of Cape Town research ethics committee, and written
informed consent was provided to collect data anonymously for
research purposes.
Setting
The study was carried out at the Hannan Crusaid Treatment
Centre (HCTC) in Gugulethu, Cape Town, which has been
described in detail previously [17,18]. This is a dedicated primary
health care clinic that has been providing ART to HIV infected
adults and children since 2002. The clinic has screened over 8000
HIV positive individuals since inception and by July 2011, 6519
adults had been initiated on ART [19]. The clinic supports a
largely low-income community of approximately 420,000 people,
with an antenatal HIV-seroprevalence of 24% in 2009 [20], and a
TB notification rate of greater than 1500/100, 000 [21].
The Treatment Centre acts as a referral HIV site for
surrounding clinics. HIV infected individuals referred to the clinic
are predominately ART naı¨ve patients. Prior to 2010, eligibility
criteria for ART included adults with a CD4 count of ,200 cells/
ul or WHO stage 4 disease. From April 2010, the eligibility criteria
were revised to include all pregnant women and patients with
tuberculosis (TB) patients who had a CD4 count ,350cell/ul [5].
Between 2002 and 2008 the first-line ART regimens consisted
of either d4T or AZT in combination with lamivudine (3TC) and
either efavirenz or nevirapine. From 2010, first line ART at the
Hannan Crusaid Clinic in ART naı¨ve adults consisted of TDF,
3TC and either efavirenz or nevirapine. However, patients that
had previously started regimens containing AZT or d4T were
maintained on these regimens unless toxicity developed.
Study Population and Design
This was a retrospective analysis involving a review of records of
HIV infected adults receiving antiretroviral therapy. The cohort
was defined as ART-naı¨ve adults starting first line ART between
September 2002 and 30 April 2011. Eligible study participants
included HIV positive adults of at least 18 years of age with a
minimum of 1 year follow-up by June 2012.
Data Collection
This study was an analysis of prospectively maintained
electronic records from this study cohort. Any missing data was
sourced from medical records. The variables collected at baseline
included: i) demographic variables including age and sex; ii)
clinical and laboratory variables including WHO staging, CD4
counts, viral loads, pregnancy status, creatinine, alanine transam-
inase (ALT) and haemoglobin; iii) Treatment variables including
ART regimen, treatment start and stop date, reasons for treatment
change, new ART regimens, outcomes and dates of outcomes.
Exposure (Determinant) and Outcomes
The primary outcome variable was risk of first drug change.
Drug changes were defined as either an individual drug
substitution from d4T, AZT and TDF due to ADRs specifically
related to that drug or a regimen switch from first-line to second-
line treatment due to development of virological failure. All
individuals were censored at first drug change and all analyses
focused on changes involving d4T, AZT and TDF.
The secondary outcomes were virological suppression and safety
of the regimens. Virological suppression was defined as a plasma
viral load less than 400 copies/ml after one year of ART. Safety
was defined as a binary variable using the following outcomes:
death, loss to follow-up, transfer out and alive and in care. Death
and loss to follow-up were used as a proxy for poor safety whilst
transfer out and alive and on ART were used as a proxy for good
safety.
The exposures (determinants) in this study were age at ART
initiation, sex, baseline CD4 count, baseline log viral load, baseline
haemoglobin, WHO staging, type of ART regimen (d4T, AZT or
TDF) and calendar year of treatment start.
Analysis and Statistics
Data analysis was conducted using STATA version 11
(StataCorp, College Station, Texas). Continuous variables were
described using means and standard deviations for normally
distributed data and medians and interquartile ranges for variables
with a skew distribution. Categorical variables were described
using percentages.
Kaplan-Meier analyses were used to measure time to first drug
substitutions due to ADRs. A second Kaplan-Meier analysis of
time to loss to follow-up/death (programme losses) was computed
to assess safety of the regimens. The risk factors associated with
drug substitutions due to ADRs were modeled using Cox
Proportional Hazards model. The model included: age at ART
initiation, sex, baseline CD4 count, baseline log viral load, baseline
haemoglobin, WHO staging, type of ART regimen and calendar
year of treatment start. A p value ,0.05 was used to denote
significance.
Results
A total of 5106 records were identified from ART naı¨ve patients
who started ART in the Gugulethu township clinic between
September 2002 and 30 April 2011. Eleven records were found to
be duplicates and were excluded. The remaining 5095 subjects
met the eligibility criteria were and were included in the analysis.
Demographic and Clinical Characteristics
Overall, the median duration on ART was 2.7 years. However,
the median exposure to TDF (1.6 years) was much shorter than for
AZT (3.1 years) or d4T (3.4 years) reflecting the later introduction
of TDF into the first-line ART regimen (Table 1). The median
ages of the patients starting treatment and proportions who were
females were similar across the TDF and d4T group. Patients
starting AZT tended to be younger and were predominately
female (90.1%) (Table 1). Overall, compared to patients starting
either AZT or TDF, those starting regimens containing d4T had
more advanced disease, as reflected by lower median CD4 counts,
higher log viral loads and a greater likelihood of having WHO
stage 3 and stage 4 disease.
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Drug Changes
The overall total person time of follow-up was 10,875.9 person
years and the cumulative person-years of exposure to each drug
was shortest for TDF (1330.9 person-years) and longest for d4T
(7875.4 person years) (Table 2). Similarly, the median time to
first drug change was significantly shorter for those in the TDF
group (1.5 years) compared to those in the AZT (2.0 years) or d4T
(1.8 years) groups (p,0.001).
Overall, use of TDF was associated with a much lower
proportion of patients undergoing drug changes (n = 73/948;
7.7%) compared to those receiving AZT (n = 189/709; 26.7%) or
d4T (n = 1597/3438; 46.5%) (Table 2). Compared to those
receiving TDF, the rates of drug changes (substitutions and
regimen switches combined) were approximately two-fold higher
among those receiving AZT and four fold higher among those
receiving d4T (5.5/100PYs [95% CI:4.3–6.8] versus 11.3/100PYs
[95% CI: 9.8–12.9] versus 20.3/100PYs [95%CI: 19.4–21.2])
respectively.
While rates of regimen switches and drug substitutions
(comprising total drug changes) were similar in the TDF group,
Table 1. Demographic and clinical characteristics of ART naı¨ve adults (n = 5095) started on ART in Hannan Crusaid Treatment
Centre.
Patient characteristics
Subjects on zidovudine
(n=709) (%)
Subjects on stavudine
(n =3438) (%)
Subjects on tenofovir
(n =948) (%)
Age (years)- median [IQR] 30.83 [26.80–36.23] 34.44 [29.62–40.94 ] 34.41 [29.35–41.04 ]
Sex
Female 639 (90.13%) 2110 (61.37%) 612 (64.56%)
WHO Stage
Asymptomatic (stage 1&2) 410 (57.83%) 727 (21.15%) 418 (44.09%)
Symptomatic (stage 3&4) 292 (41.18%) 2,700 (78.53%) 492 (51.90%)
No information 7 (0.99%) 11 (0.32%) 38 (4.01%)
Pregnant
Pre-ART 340 (47.95%) 57 (1.66%) 68 (7.17%)
On ART 1 (0.14%) 19 (0.55%) 1 (0.11%)
No information 368 (51.90%) 3,362 (97.79%) 879 (92.72%)
NNRTI/PI based
Efavirenz 183 (25.81%) 2,360 (68.64%) 838 (88.40%)
Nevirapine 523 (73.77%) 1,075 (31.27%) 110 (11.60%)
Liponavir/ritonavir 3 (0.42%) 3 (0.09%) 0 (0%)
Median ART duration (years)- median [IQR] 3.10 [1.40–4.70] 3.40 [1.50–5.70] 1.60 [1.20–1.90]
Baseline log viral load (copies/ml)- median [IQR] 4.60 [4.08–5.02] 4.94 [4.51–5.35] 4.65 [4.16–5.15]
Baseline CD4 count (mmol/l)- median [IQR] 139 [89–189] 103 [49–164] 153 [81–215]
Baseline haemoglobin (g/dl)- median [IQR] 10.7 [9.80–11.80] 11.1 [9.70–12.40] 11.64 [10.2–12.90]
Baseline ALT- median [IQR] 19 [12–29] 25 [17–37] 19 [14–30]
Baseline creatinine (mmol/l)- median [IQR] 72 [57–88] 75 [62–91] 64 [54–74]
IQR- Interquartile range; ART- antiretroviral therapy; NNRTI- Non-nucleoside reverse transcriptase inhibitors; PI-Protease inhibitor; ALT- alanine transaminase.
doi:10.1371/journal.pone.0063596.t001
Table 2. Numbers and rates of d4T, AZT and TDF first drug changes during follow-up.
Type of drug change Subjects on zidovudine (n =709) Subjects on stavudine (n =3438) Subjects on tenofovir (n = 948)
Median time (years) to first drug change
[IQR]
2.0 [0.6–3.8] 1.8 [0.8–3.3] 1.5 [1.0–1.9]
Total time exposed (person years) 1669.6 7875.4 1330.9
Total drug changes 189 (26.7%) 1597 (46.5%) 73 (7.7%)
Rate of total drug changes (/100PY) 11.3 (95% CI: 9.8–12.9) 20.3 (95% CI: 19.4–21.2) 5.5 (95% CI: 4.3–6.8)
Drug substitutions 142 1409 35
Rate of drug substitutions (/100PY) 8.5 (95% CI: 7.2–9.9) 17.9 (95% CI: 17.1–18.8) 2.6 (95% CI: 1.8–3.6)
Regimen switch 47 188 38
Rate of regimen switches (/100PY) 2.8 (95% CI: 2.1–3.7) 2.4 (95% CI: 2.1–2.7) 2.9 (95% CI: 2.0–3.9)
IQR- Interquartile range.
doi:10.1371/journal.pone.0063596.t002
Antiretroviral Switch Rates Pre/Post Tenofovir
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e63596
drug substitutions accounted for a larger majority of drug changes
among those receiving d4T or AZT (Table 2).
Viral load suppression rates were similar for the three different
drug exposure groups, ranging between 89% and 90% after 1 year
of ART (data not shown). Similarly, rates of regimen switch were
comparable across all three exposure groups suggesting that
similar rates of virological failure were associated with these
regimens, ranging between 2.4 and 2.9 switches/100PYs
(Table 2). In contrast, rates of individual drug switch differed
markedly with d4T having higher rates of drug substitution rates
(17.9/100PY; 95% CI: 17.1–18.8) compared to TDF (2.6/100PY;
95% CI: 1.8–3.6) and AZT (8.5/100PY; 95% CI: 7.2–9.9)
(Table 2).
Reasons for Drug Changes
Overall, a majority of individuals had a single reason for drug
changes, with a small proportion of subjects having more than one
reason recorded. Seventy-three subjects on TDF experienced a
drug change, with a total of 77 recorded causes; 189 subjects on
AZT experienced a first drug change, with a total of 192 recorded
causes; 1597 subjects on d4T had a drug change with a total of
1623 recorded causes (Table 3).
ADRs accounted for a much smaller proportion of TDF
changes (20.8%) compared to AZT (30.2%) or d4T (74.1%).
Pregnancy (primarily women in the post-natal period) was
associated with numerous AZT substitutions, (32.3%) but smaller
proportions of d4T substitutions (8.9%) or TDF substitutions
(6.5%). Drug substitution in relation to tuberculosis was uncom-
mon in d4T and AZT group but occurred more frequently in TDF
group (Table 3). This could be due to the practice of not
prescribing TDF together with aminoglycosides in retreatment or
drug resistant tuberculosis, as both drugs are potentially nephro-
toxic.
Types of Adverse Drug Reactions
Renal impairment, lipodystrophy and anaemia were the most
frequently occurring ADRs. The ADRs most commonly resulting
in drug substitution were anaemia in those receiving AZT,
lipodystrophy in those receiving d4T and renal impairment in
those receiving TDF (Table 4). Cumulatively, 18.1% (623/3438)
required drug substitutions due to d4T-related lipodystrophy
compared to 4.2% (30/709) from AZT associated anaemia and
1.2% (11/948) from TDF associated renal impairment. Within the
sub group of individuals requiring drug substitution due to ADRs
only, just over half of subjects 623 (51.8%) switching d4T did so
due to lipodystrophy, 30 (51.7%) patients substituting AZT did so
due to anaemia and 11 (68.8%) of patients substituting TDF did so
due to renal impairment (Table 4).
A Kaplan-Meier plot, (Figure 1), shows that d4T was
associated with the highest risk of drug substitutions due to ADRs
over time, whereas TDF was associated with the lowest risk
(p,0.001). After 1 year on ART, the proportions of patients who
had substituted TDF, AZT or d4T were 1.6%, 5% and 10.5%
respectively. By 8 years on ART, 35% (1202/3438) of d4T
subjects had a drug substitution due to side effects compared to
8.2% (58/709) subjects on AZT. In contrast, a Kaplan-Meier plot
of time to loss to follow-up or death showed no significant
Table 3. Reasons for drug changes due to d4T, AZT and TDF at any time during ART (1 change may occur due to more than one
reason).
Reason for drug change Zidovudine (n =192) Stavudine (n=1623) Tenofovir (n = 77)
Side effect 58 (30.2%) 1202 (74.1%) 16 (20.8%)
Regimen switch due to virological failure 47 (24.5%) 188 (11.6%) 38 (49.4%)
Pregnancy related 62 (32.3%) 145 (8.9%) 5 (6.5%)
Tuberculosis 4 (2.1%) 8 (0.5%) 16 (20.8%)
Defaulted treatment 12 (6.3%) 39 (2.4%) 1 (1.3%)
Hepatitis B 2 (1.0%) 6 (0.4%) 0 (0%)
Other 5 (2.6%) 21 (1.3%) 1 (1.3%)
Reason not stated 2 (1.0%) 14 (0.9%) 0 (0%)
doi:10.1371/journal.pone.0063596.t003
Table 4. Types of adverse drug reactions resulting in drug substitution in d4T, AZT and TDF (denominator = number of patients
with drug substitution due to side effects from table 3).
Adverse drug reaction Zidovudine (n =58) Stavudine (n =1202) Tenofovir (n = 16)
Lipodystrophy 12 (20.7%) 623 (51.8%) 0 (0%)
Peripheral neuropathy 7 (12.1%) 454 (37.8%) 0 (0%)
Renal impairment 0 (0%) 0 (0%) 11 (68.8%)
Anaemia 30 (51.7%) 6 (0.5%) 5 (31.3%)
Hyperlactataemia 0 (0%) 67 (5.6%) 0 (0%)
Lactic acidosis 0 (0%) 13 (1.1%) 0 (0%)
Other 9 (15.5%) 39 (3.2%) 0 (0%)
doi:10.1371/journal.pone.0063596.t004
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difference between the three groups suggesting that losses to the
programme were similar across groups (Figure 2).
Univariate and Multivariate Data Analysis of First Drug
Substitution Due to Adverse Drug Reactions
Univariate and multivariate data analyses of time to first drug
substitution due to ADRs were done. In univariate analysis,
age.40 years, advanced WHO stage disease, lower CD4 count,
higher viral load and d4T use were all associated with an increased
hazard of drug substitution due to ADRs. Conversely, use of TDF
was associated with a lower risk of switching (Table 5).
In the multivariate data analysis, using AZT as a comparator,
d4T regimens were independently associated with substantially
increased risk (adjusted hazard ratio 4.89; 95% CI: 3.72–6.44) of
substitution whereas the risk among those receiving TDF was
substantially lower (adjusted hazard ratio, 0.38; 95% CI: 0.20–
0.72) (Table 5).
Figure 1. Kaplan-Meier estimates of time to first drug substitution due to ADRs in d4T, AZT and TDF.
doi:10.1371/journal.pone.0063596.g001
Figure 2. Kaplan-Meier estimates of time to programme losses (loss to follow-up/death) in adults initiated on ART.
doi:10.1371/journal.pone.0063596.g002
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Discussion
We describe rates of first drug substitutions due to ADRs and
regimen switches due to virological failure in a large cohort of
ART naı¨ve adults with 10, 875.9 person years of follow-up. This
study reports on the rates of drug changes over a ten year period
(2002–2012) that spanned the introduction of TDF based ART in
South Africa. We observed that TDF was the best tolerated drug
with the fewest drug substitutions due to ADRs. All three regimens
appear equally effective with similar rates of virological suppres-
sion at 1 year on ART and similar regimen switch rates due to
virological failure.
Overall, TDF based regimens had a lower drug substitution rate
compared to d4T and AZT. Our results are similar to data from a
Zambian cohort as well as a cohort of treatment naı¨ve adults
followed up over 7 years in Johannesburg, South Africa [10,22]
Toxicity was a common reason for drug substitution across the
three patient groups. We observed that TDF was the best tolerated
drug with fewer drug substitutions attributed to toxicity, whilst
d4T based regimens were the least tolerated. This trend has also
been reported in other resource limited settings as well as in
developed settings [10,15,22,23] although our study reported
higher proportions of drug substitutions due to ADRs, possibly due
to the longer follow up period in our study compared to previous
studies or differences in clinical practice.
Lipodystrophy and peripheral neuropathy were the two major
toxicities resulting in d4T drug substitutions, whilst anaemia was
the most common ADR resulting in drug substitution in AZT as
reported by other studies [8,9,11]. However, we found a
substantially higher proportion of patients required d4T substitu-
tion due to ADRs compared to previous studies. This may be a
function of longer follow-up and/or tendency to conserve first line
regimens in other settings. Compared to d4T and AZT toxicities,
TDF was more commonly associated with renal impairment
although only 11 (1.2%) patients substituted TDF due to this
ADR. Other observational and experimental studies have reported
similar low rates of TDF substitution due to renal impairment
[12,14].
Virological suppression rates at one year were similar for all
three regimens, suggesting similar short term virological efficacy.
By 9 years on ART, few patients from the cohort (5.4%) had a
regimen switch due to virological failure, and rates of regimen
switching for virological failure were similar for all three regimens.
The overall low rates of regimen switching may reflect reluctance
of clinicians to switch patients to second-line regimens due to
limited treatment options. Alternatively, the regimen switch rates
reported in this study were an underestimation of the true
virological failure rates as they excluded patients who failed to
switch to second-line therapy due to programme losses. Never-
theless, our findings are similar to other studies from resource
limited settings [11,24,25]. Kaplan-Meier plots showed that losses
to the programme (death/loss to follow-up) were comparable
across groups, a finding that has been reported in other cohorts
[10,26]. This further underscores the benefit of TDF as a first line
agent as it has a better safety profile and equal effectiveness to d4T
and AZT.
Multivariate analysis showed that d4T and AZT regimens were
associated with an increased hazard of drug substitution due to
ADRs compared to TDF based regimens. This further highlights
the better safety profile associated with TDF compared to other
NRTIs (d4T and AZT). These findings have been reported in both
developing settings and first world settings [10,16,22]. Increasing
age is a known risk factor for ADRs such as lipodystrophy,
peripheral neuropathy and renal impairment [3]. In adjusted
analysis, female sex and age.40 years were also associated with an
increased hazard of drug substitution. Female sex has been
identified as a strong predictor of drug substitution in multiple
studies [9,10,22]. In contrast, data on the association between
increasing age and drug substitution are less consistent, with some
studies reporting no association whilst others reporting a decreased
risk [10,22]. A large number of individuals required drug
substitution due to d4T-induced lipodystrophy and peripheral
neuropathy which may explain the association between increasing
age and drug substitutions.
Study limitations include the fact that the analysis was restricted
to time to first drug change only, thereby underestimating the true
number of overall drug changes. Second, data was only available
for approximately two years for TDF regimens compared to nine
years for AZT and d4T regimens, so possibly underestimating
TDF drug changes in the long term. Third, TDF use was preceded
by a change in ART guidelines; hence some of the differences
observed may be confounded by changes in ART policy and
clinical practices. Nonetheless, this study is based on a robust
dataset, with a large sample size, long follow-up period and
minimal missing data in the described variables.
In conclusion, rates of virological suppression and regimen
switching due to virological failures were similar for patients
Table 5. Cox Proportional Hazard model of risk factors for
time to first drug substitution due to adverse drug reactions.
Univariate Analysis Multivariate analysis
Variable Hazard ratio 95% CI Hazard ratio 95% CI
Age (years)
Age #40 Reference
Age .40 1.49 1.32–1.68 1.48 1.30–1.68
Sex
Female Reference
Male 0.91 0.80–1.02 0.72 0.63–0.82
Baseline CD4 count
CD4,200 Reference
CD4$200 0.77 0.65–0.91 0.97 0.81–.1.16
WHO staging
Asymptomatic (stage
1&2)
Reference
Symptomatic (stage 3
&4)
1.47 1.29–1.68 0.97 0.84–1.11
Baseline log viral load 1.26 1.15–1.37 1.10 1.00–1.21
Baseline haemoglobin
(g/dl)
0.96 0.93–0.99 0.98 0.95–1.0
ART regimen
Zidovudine Reference
Stavudine 4.99 3.84–6.50 4.89 3.72–6.44
Tenofovir 0.38 0.22–0.67 0.38 0.20–0.72
Year of ART
initiation
2002–2005 Reference
2006–2007 0.76 0.67–0.87 0.80 0.70–0.93
2008–2009 0.83 0.72–0.96 0.98 0.84–1.14
2010–2011 0.19 0.14–0.26 1.06 0.72–1.57
doi:10.1371/journal.pone.0063596.t005
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exposed to TDF, d4T and AZT, suggesting these regimens were
equally effective. However, TDF was better tolerated with a
substantially lower rate of drug substitutions due to adverse drug
reactions. These findings support the national policy to include
TDF in first-line ART regimens. Further studies with longer
durations of follow-up will be required to determine the long term
safety and effectiveness of TDF.
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